e16160 Background: Surgical resection is the primary radical treatment for hepatocellular carcinoma (HCC). However, the percentage of initially resectable HCC is only 15-30%, and most patients are unable to undergo surgical resection at the time of initial diagnosis. Lenvatinib combined with PD-1 inhibitor and transarterial intervention has demonstrated good efficacy and safety in unresectable HCC. The retrospective study was designed to explore the safety and conversion effects of lenvatinib + camrelizumab+ HAIC in potentially resectable HCC. Methods: In this single-arm retrospective study, investigators collected patients with potentially resectable HCC treated with lenvatinib + camrelizumab + HAIC from November 2020 to December 2022. The potentially resectable population was selected by the following screening criteria: acceptable liver function (Child-Pugh A-B), good ECOG PS (0-1), intrahepatic tumors confined to one lobe (left, right, or middle lobe), and unresectable by surgical or oncological causes. Results: A total of 64 patients with potentially resectable HCC were included in this analysis. The conversion rate was 31.25% (20), and 23.4% (15) patients underwent surgery. The ORR and DCR were 56.3% and 85.9% by RECIST 1.1. Progression had occurred in 8 patients by the data cutoff on November 1, 2022. The median follow-up time was 13.6 months (range: 2.9-23.7) and 8 patients died. The data was not yet mature, with 1-year survival rate of 90.7%, Overall, 65.6% of patients experienced at least one treatment emergent adverse event (TEAE) and 15.6% of patients had Grade 3/4 TEAE, the most common was hand and foot syndrome (7.8%, n=5). Conclusions: Lenvatinib combined with PD-1 inhibitor and HAIC was well tolerated and showed potential conversion efficacy in the treatment of patients with potentially resectable HCC.
Read full abstract